Catalyst
Slingshot members are tracking this event:
U.S. FDA Approves Two Supplemental Indications for Harvoni in Chronic Hepatitis C Patients With Advanced Liver Disease
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
GILD |
|
|
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 16, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fda, Harvoni, Chronic Hepatits C, Liver Disease, Chronic Hepatitis C Virus, Liver Transplant, Ledipasvir, Sofosbuvir, Chronic Hepatitis C